Surgical versus medical treatment for ocular surface squamous neoplasia: A quality of life comparison.


Journal

The ocular surface
ISSN: 1937-5913
Titre abrégé: Ocul Surf
Pays: United States
ID NLM: 101156063

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 03 2018
revised: 08 07 2018
accepted: 06 09 2018
pubmed: 16 9 2018
medline: 2 6 2020
entrez: 16 9 2018
Statut: ppublish

Résumé

To characterize vision-related and psychosocial quality of life (QoL) parameters in medically and surgically treated patients with OSSN. Forty-one patients with OSSN treated with medical therapy consisting of interferon alpha 2b drops 1 MIU/ml (n = 22) or who underwent surgical excision (n = 19) were contacted. All subjects answered a quality of life assessment with an original questionnaire in which they were asked about a range of parameters. Overall satisfaction and motivating factors for treatment were also reviewed. The mean age at the time of the survey was 64.6 and 51% were male with similar demographics between groups. Based on the previous cohort, rates of tumor resolution and recurrences were comparable in the two groups. Reasons for choosing a particular treatment varied between the groups. Forty percent of individuals in the medical group reported a fear of surgery (p = 0.03) and often made the decision after personal research (p = 0.008). Thirty-two percent of patients in the surgical group chose surgery due to fear of decreased vision due to lesion growth, therefore wanting immediate resolution (p = 0.09). Drops precipitated more ocular symptoms such as tearing and itchiness, on the other hand, patients who had surgery reported having more pain. Quality of life considerations before, during, and after OSSN treatment is an important yet understudied topic. Our study is the first to look at QoL parameters in OSSN treatment and we found that patients in both medically and surgically treated groups had similar QoL metric but were driven to choose chemotherapy due to fear of surgery and/or prior literature review.

Identifiants

pubmed: 30217629
pii: S1542-0124(18)30068-5
doi: 10.1016/j.jtos.2018.09.001
pmc: PMC6340727
mid: NIHMS1512977
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Interferon alpha-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-63

Subventions

Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Références

Am J Public Health. 2011 May;101(5):848-53
pubmed: 21421943
J Clin Oncol. 2001 Mar 15;19(6):1809-17
pubmed: 11251013
J Am Acad Dermatol. 2008 Sep;59(3):439-47
pubmed: 18639364
J Ocul Pharmacol Ther. 2015 Oct;31(8):487-90
pubmed: 26114378
Qual Life Res. 2016 Feb;25(2):465-475
pubmed: 26238649
J Invest Dermatol. 1996 Nov;107(5):707-13
pubmed: 8875954
PeerJ. 2018 Apr 27;6:e4604
pubmed: 29719731
J Chronic Dis. 1981;34(12):585-97
pubmed: 7309824
Obes Surg. 2017 Jul;27(7):1684-1690
pubmed: 28058616
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Asian Pac J Cancer Prev. 2014;15(24):10871-4
pubmed: 25605192
Ophthalmology. 2014 May;121(5):994-1000
pubmed: 24411578
Cancer. 1998 Jul 1;83(1):173-9
pubmed: 9655308
Eye (Lond). 2013 Oct;27(10):1223-4
pubmed: 23907623
Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24
pubmed: 14711437
Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):109-120
pubmed: 28399347
Eye (Lond). 2012 Jun;26(6):781-7
pubmed: 22402703
Headache. 2010 Apr;50(4):528-38
pubmed: 20236340
Ophthalmology. 2016 Mar;123(3):497-504
pubmed: 26686965
Clin Exp Ophthalmol. 2015 Jan-Feb;43(1):20-5
pubmed: 24995542
Psychooncology. 2011 Jun;20(6):572-84
pubmed: 21442689
Psychooncology. 2012 Oct;21(10):1099-106
pubmed: 21830256
Cancer. 1991 Jun 15;67(12):3131-5
pubmed: 1710541
Ophthalmology. 1997 Feb;104(2):334-42
pubmed: 9052642
Qual Life Res. 2014 Feb;23(1):135-43
pubmed: 23733663
Cornea. 2016 May;35(5):613-8
pubmed: 26890663
Spine J. 2012 Dec;12(12):1122-8
pubmed: 23158968

Auteurs

Carolina L Mercado (CL)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Cameron Pole (C)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

James Wong (J)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Juan F Batlle (JF)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Fabiola Roque (F)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Noah Shaikh (N)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Juan C Murillo (JC)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA.

Anat Galor (A)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA; Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA.

Carol L Karp (CL)

Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA. Electronic address: ckarp@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH